Log in

NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News

$13.15
-0.62 (-4.50 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.50
Now: $13.15
$13.95
50-Day Range
$12.59
MA: $15.29
$20.28
52-Week Range
$3.19
Now: $13.15
$26.00
Volume402,280 shs
Average Volume392,996 shs
Market Capitalization$80.61 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.72
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.
Read More
Bellerophon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLPH
CUSIPN/A
Phone908-574-4770

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.78 per share

Profitability

Net Income$-13,270,000.00

Miscellaneous

Employees17
Market Cap$80.61 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

How has Bellerophon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLPH shares have increased by 109.1% and is now trading at $13.15. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bellerophon Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellerophon Therapeutics.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Bellerophon Therapeutics.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics Inc (NASDAQ:BLPH) released its earnings results on Monday, May, 11th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.02) by $0.13. View Bellerophon Therapeutics' earnings history.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

3 analysts have issued 12 month target prices for Bellerophon Therapeutics' shares. Their forecasts range from $30.00 to $35.00. On average, they expect Bellerophon Therapeutics' share price to reach $31.67 in the next twelve months. This suggests a possible upside of 140.8% from the stock's current price. View analysts' price targets for Bellerophon Therapeutics.

Has Bellerophon Therapeutics been receiving favorable news coverage?

News coverage about BLPH stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bellerophon Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutBellerophon Therapeutics.

Are investors shorting Bellerophon Therapeutics?

Bellerophon Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 87,600 shares, a drop of 21.1% from the April 30th total of 111,000 shares. Based on an average trading volume of 973,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.7% of the shares of the company are short sold. View Bellerophon Therapeutics' Current Options Chain.

Who are some of Bellerophon Therapeutics' key competitors?

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Vaxart (VXRT), Novavax (NVAX), VBI Vaccines (VBIV), Opko Health (OPK), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Clovis Oncology (CLVS).

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Fabian Tenenbaum, Chief Executive Officer & Director
  • Assaf Korner, Chief Financial Officer & Secretary
  • Amy Edmonds, VP-Clinical Operations & Administration
  • Martin Dekker, Vice President-Engineering & Manufacturing
  • Peter Fernandes, Chief Regulatory & Safety Officer

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include New Mountain Vantage Advisers L.L.C. (1.63%), Telemetry Investments L.L.C. (0.82%), Credit Agricole S A (0.05%) and Morgan Stanley (0.04%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin and Theodore T Wang. View institutional ownership trends for Bellerophon Therapeutics.

Which institutional investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including New Mountain Vantage Advisers L.L.C., and Telemetry Investments L.L.C.. View insider buying and selling activity for Bellerophon Therapeutics.

Which institutional investors are buying Bellerophon Therapeutics stock?

BLPH stock was acquired by a variety of institutional investors in the last quarter, including Credit Agricole S A, and Morgan Stanley. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Naseem Amin, and Theodore T Wang. View insider buying and selling activity for Bellerophon Therapeutics.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $13.15.

How big of a company is Bellerophon Therapeutics?

Bellerophon Therapeutics has a market capitalization of $80.61 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.